A novel Tc-99 m and fluorescence labeled peptide as a multimodal imaging agent for targeting angiogenesis in a murine hindlimb ischemia model. (March 2017) - Hyoun Kim, Myoung
Abstract: The serine-aspartic acid-valine (SDV) peptide binds specifically to integrin αvβ3. We developed a Tc-99 m and TAMRA labeled peptide, Tc-99 m SDV-ECG-K-TAMRA for multimodal imaging of angiogenesis. Tc-99 m SDV-ECG-K-TAMRA was prepared in high yield (>96%) and showed low cytotoxicity. Tc-99 m tetrofosmin images 1 week after operation, revealed significantly decreased perfusion of the ischemic hindlimb, and the perfusion recovered gradually for 4 weeks. In contrast, Tc-99 m SDV-ECG-K-TAMRA uptake was maximal 1 week after the operation (ischemic-to-non-ischemic uptake ratio =5.03±1.01) and decreased gradually. The ischemic-to-non-ischemic ratio of Tc-99 m SDV-ECG-K-TAMRA and Tc-99 m tetrofosmin was strongly negatively correlated (r =−0.94). A postmortem analysis revealed increased angiogenesis markers and uptake of Tc-99 m SDV-ECG-K-TAMRA by ischemic tissue. Our in vivo and in vitro studies revealed substantial uptake of Tc-99 m SDV-ECG-K-TAMRA by ischemic tissue. Tc-99 m SDV-ECG-K-TAMRA could be a good candidate dual-modality imaging agent to assess angiogenesis. Highlights: Dual-modality imaging agent, Tc-99 m SDV-ECG-K-TAMRA was prepared for angiogenesis imaging. Increased uptake of Tc-99 m SDV-ECG-K-TAMRA in ischemic tissue was demonstrated by in vivo and in vitro imagings. Tc-99 m SDV-ECG-K-TAMRA could be a good candidate dual-modality imaging agent to assess angiogenesis.